Andrew Callos Sells 1,930 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Posted by Jeff Wilder on Mar 20th, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Andrew Callos sold 1,930 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $62.07, for a total transaction of $119,795.10. Following the completion of the transaction, the executive vice president directly owned 78,185 shares in the company, valued at $4,852,942.95. This represents a 2.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Andrew Callos also recently made the following trade(s):

On Tuesday, March 17th, Andrew Callos sold 8,542 shares of Cytokinetics stock. The shares were sold at an average price of $62.15, for a total value of $530,885.30.
On Monday, March 16th, Andrew Callos sold 1,709 shares of Cytokinetics stock. The stock was sold at an average price of $61.03, for a total value of $104,300.27.
On Monday, March 9th, Andrew Callos sold 2,582 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total value of $156,779.04.
On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.87, for a total value of $1,608,620.00.
On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $61.93, for a total value of $928,950.00.
On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The stock was sold at an average price of $62.10, for a total value of $55,020.60.
On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $60.28, for a total value of $904,200.00.
On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The shares were sold at an average price of $62.62, for a total value of $112,590.76.
On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The shares were sold at an average price of $62.44, for a total transaction of $112,953.96.

Cytokinetics Stock Performance

Cytokinetics stock opened at $62.95 on Friday. Cytokinetics, Incorporated has a one year low of $29.31 and a one year high of $70.98. The company has a 50-day simple moving average of $63.79 and a 200-day simple moving average of $60.95. The firm has a market capitalization of $7.75 billion, a P/E ratio of -9.64 and a beta of 0.56.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The company had revenue of $17.76 million for the quarter, compared to analysts’ expectations of $8.02 million. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.26) EPS. As a group, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. raised its holdings in Cytokinetics by 842.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 641 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 573 shares in the last quarter. Corient Private Wealth LLC boosted its stake in Cytokinetics by 46.4% during the 4th quarter. Corient Private Wealth LLC now owns 7,044 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 2,231 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Cytokinetics during the 4th quarter valued at $657,000. Alpine Global Management LLC acquired a new position in shares of Cytokinetics during the 4th quarter valued at $381,000. Finally, Pacer Advisors Inc. raised its stake in shares of Cytokinetics by 76.5% in the 4th quarter. Pacer Advisors Inc. now owns 27,783 shares of the biopharmaceutical company’s stock worth $1,765,000 after buying an additional 12,043 shares in the last quarter.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Mizuho raised its price target to $100 and kept an “outperform” rating, implying meaningful upside vs. the current share price — a catalyst for momentum buying. Mizuho raises target to $100
Positive Sentiment: JPMorgan raised its target to $75 and maintained an overweight stance, adding institutional analyst support that can attract fund flows. JPMorgan raises target to $75
Positive Sentiment: Large institutional holders (e.g., Vanguard, State Street) have been increasing positions, which supports longer‑term demand and underpins current price strength. Institutional holdings update
Neutral Sentiment: Cytokinetics granted inducement awards (8,628 options and 5,719 RSUs) to five new hires under Nasdaq Rule 5635(c)(4); standard hiring comp — modest future dilution but intended to secure talent. Inducement grants
Neutral Sentiment: Latest quarter showed a slight EPS miss but a revenue beat — mixed fundamentals that appear secondary to the recent analyst target moves in driving sentiment. Earnings recap
Neutral Sentiment: Reported short‑interest data for March appears inconsistent/empty and is not a clear near‑term signal (days‑to‑cover shown as 0.0), so treat that item as noise until clarified by exchanges.
Negative Sentiment: Significant insider selling: CEO Robert Blum sold ~36,601 shares (~$2.27M) and multiple EVPs sold large blocks across March. Large, clustered insider disposals can create short‑term selling pressure or be interpreted as diversification — worth monitoring for follow‑through. Insider selling details

Analyst Ratings Changes

Several brokerages have recently issued reports on CYTK. Robert W. Baird set a $84.00 price objective on Cytokinetics in a research report on Tuesday, March 10th. Truist Financial raised their target price on Cytokinetics from $84.00 to $92.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. HC Wainwright lifted their target price on Cytokinetics from $120.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Royal Bank Of Canada boosted their price target on Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Finally, The Goldman Sachs Group set a $95.00 price target on Cytokinetics and gave the stock a “buy” rating in a research note on Thursday, December 18th. Seventeen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $89.89.

Get Our Latest Report on CYTK

Cytokinetics Company Profile

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.